Physician profile
Niraj Nathan
NPI 1588920060
$2,231.58
in general payments reported to CMS, 2019-2025
15 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $79.90 · 2021: $216 · 2023: $849 · 2024: $702 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $53.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.95 |
| Education | $53.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $683.30 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Sight Sciences, INC. | $487.48 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $278.68 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $166.33 | 2023-2025 | Miebo, Envista Mx60 Iol, Ic-8 Apthera Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.89 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $130.21 | 2023 | Tecnis Iol |
| Allergan, INC. | $79.90 | 2020 | |
| Oyster Point Pharma, INC. | $62.59 | 2023 | Tyrvaya |
| Glaukos Corporation | $43.03 | 2024 | Idose |
| Harrow Eye, LLC | $38.08 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $36.23 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $30.91 | 2024 | |
| Dompe US, INC. | $28.92 | 2024 | Oxervate |
| Biotissue Holdings INC. | $22.82 | 2024 | |
| Iridex Corporation | $12.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.